InvestorsHub Logo
Followers 829
Posts 119691
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 705

Friday, 07/29/2022 11:51:45 AM

Friday, July 29, 2022 11:51:45 AM

Post# of 751
ABBV 2Q22 results:

https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-second-quarter-2022-financial-results

2022 non-GAAP EPS guidance is unchanged at $13.78-13.98, including a $0.23 charge for in-process R&D during 1H22, but no IPR&D charge relating to 2H22 insofar as M&A activity during 1H22 is not yet known

ABBV set aside $2B to settle opioid litigation (https://finance.yahoo.com/news/1-abbvie-sets-aside-2-121111751.html ), but this charge is excluded from the non-GAAP results are guidance.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News